A phase II study of Bevacizumab plus Pemetrexed for previously treated Non Small Cell Lung Cancer with T790M mutatio
Phase 2
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000008032
- Lead Sponsor
- Toho University Omori Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of hemoptysis ( >= 2.5mL) 2) History of continuous hemosputum 3) Untreated Brain metastasis 4) Previously treated with Pemetrexed 5) Receiving a blood transfusion, hematopoietic factor, anticoagulant drug 2 weeks prior to enrollment 6)Patients with active severe infections 7) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 8) Current or previous history of GI perforation 9) Patients with uncontrollable complications 10) Pregnancy, breast feeding and suspected pregnancy 11) Active concomitant malignancy 12)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Progression free survival Safety